ASX ANNOUNCEMENT

7 September 2026

Saluda Medical CEO Transition

Saluda Medical, Inc. (**ASX:SLD**, "**Saluda**" or the "**Company**"), today announced the Board has appointed Mr Mike Mathias, who is currently Saluda's Chief Commercial Officer, as its new Chief Executive Officer, replacing Mr Barry Regan.

Mr Mathias joined Saluda as Chief Commercial Officer in November 2024 and has played a pivotal role in the Company's global commercial strategy and execution. Prior to Saluda, he spent more than 30 years of healthcare and medical technology experience, including senior commercial and operational leadership roles at Medtronic, LimFlow and Endologix. His existing knowledge of Saluda's technology, customers, people and strategic priorities provides continuity through the leadership transition.

Mr Doug Godshall, Chair of Saluda said: *"On behalf of the Board, I would like to sincerely thank Barry for his leadership and contribution to Saluda. During his tenure, Barry helped advance the Company's strategic and operating priorities and strengthened the foundations for Saluda's next phase of development and growth. The Board is pleased to appoint Mike as Chief Executive Officer given his extensive knowledge of Saluda, its technology, customers and commercial opportunity, together with substantial strategic and operational leadership experience. His appointment provides strong continuity while positioning the Company to continue executing its stated strategy and creating long-term shareholder value. The* Company *has a strong and experienced leadership team, and the Board is confident in the continuity of strategy, operational delivery and financial discipline."*

Mr Mathias also commented: *"I am honoured to be appointed Chief Executive Officer of Saluda. Since joining the Company, I have seen first-hand the strength of our technology, the commitment of our people and the significant opportunity ahead of us. My immediate focus will be on supporting our teams, serving our customers and their patients,* while *maintaining disciplined execution of our strategic priorities. I thank Barry Regan for his leadership during his tenure. The Company's strategy and near-term operating priorities remain unchanged."*

Mr Mathias will remain on his existing employment terms until the new arrangements are finalised. A further announcement will then be made advising of the material terms of Mr Mathias' new CEO employment contract.

This announcement has been authorised for release by Saluda Medical's Board of Directors.

For more information, please contact:

Investors		**Media**
James Erickson	Sam Wells	Matt Wright
Chief Financial Officer	NWR Communications	NWR Communications
investors@saludamedical.com	+61 (0) 427 630 152	+61 (0) 451 896 420
	sam@nwrcommunications.com.au	matt@nwrcommunications.com.au

SALUDA MEDICAL, INC.
ARBN 691 140 360
9401 James Ave S, Suite 132
Bloomington MN 55431, United States

About Saluda Medical

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/.

Foreign Ownership Restriction

Saluda's CHESS Depositary Interests (CDIs) are issued in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), and a no-action letter issued by the staff of the U.S. Securities and Exchange Commission. Accordingly, the Company's CDIs have not been, and will not be, registered under the U.S. Securities Act (except pursuant to an effective registration statement) or the securities laws of any state or other jurisdiction in the United States. The holders of Saluda's CDIs may not offer, sell, pledge, or otherwise transfer the CDIs into the United States or to, or for the account or benefit of, a "U.S. Person" (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act) for a period of at least 12 months from the allotment date under the IPO, unless the resale of the CDIs is registered under the U.S. Securities Act or an exemption from registration is available.

SALUDA MEDICAL, INC.
ARBN 691 140 360
9401 James Ave S, Suite 132
Bloomington MN 55431, United States